CA2458146A1 - Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection - Google Patents

Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection Download PDF

Info

Publication number
CA2458146A1
CA2458146A1 CA002458146A CA2458146A CA2458146A1 CA 2458146 A1 CA2458146 A1 CA 2458146A1 CA 002458146 A CA002458146 A CA 002458146A CA 2458146 A CA2458146 A CA 2458146A CA 2458146 A1 CA2458146 A1 CA 2458146A1
Authority
CA
Canada
Prior art keywords
delivery system
mixture
milk
apoprotein
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002458146A
Other languages
French (fr)
Other versions
CA2458146C (en
Inventor
Michael Anthony Folan
Damien Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westgate Biological Ltd
Original Assignee
Westgate Biological Limited
Michael Anthony Folan
Damien Brady
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westgate Biological Limited, Michael Anthony Folan, Damien Brady filed Critical Westgate Biological Limited
Publication of CA2458146A1 publication Critical patent/CA2458146A1/en
Application granted granted Critical
Publication of CA2458146C publication Critical patent/CA2458146C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

The present invention relates to use of a milk apoprotein or a mixture there of to prevent or treat microbial or viral infection of the human or animal body . It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereo f is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and/or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, e ye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

Claims (32)

1. The use of a milk apoprotein or a mixture thereof to inhibit adhesion of potential pathogens in or on a surface of the human and animal body.
2. The use of a milk apoprotein or a mixture thereof for the manufacture of a medicament for inhibiting adhesion of potential pathogens in or on a surface of the human or animal body.
3. A pharmaceutically acceptable delivery system comprising at least one milk apoprotein, or a mixture thereof, in a pharmaceutically acceptable carrier.
4. A use or a delivery system according to any one of the preceding claims, in which the, or each, milk apoprotein is a milk apolipoprotein.
5. A use or a delivery system according to Claim 4, in which the, or each, milk apolipoprotein is derived from a milk lipoprotein selected from beta-lactoglobulin, fat globule membrane and alpha-lactalbumin or a mixture thereof.
6. A use or a delivery system according to any one of the preceding claims, in which the milk apoprotein or the mixture thereof is prepared by hydrolysing milk serum or milk whey with an enzyme(s), preferably a lipase(s);
denaturing the enzyme(s); and separating the apoprotein(s)-rich fraction.
7. A use or a delivery system according to any one of Claims 1-5, in which the milk apoprotein or the mixture thereof is prepared by hydrolysing milk serum or milk whey with an enzyme(s), preferably a lipase(s).
8. A use or a delivery system according to any one of the preceding claims, in which the milk is cow or goat milk.
9. A use or a delivery system according to any one of the preceding claims, further comprising at least one free fatty acid or a mixture thereof; or a monoglyceride thereof, or a mixture thereof.
10. A use or a delivery system according to Claim 9, in which the, or each, fatty acid is saturated or unsaturated and has a hydrocarbon chain with an even number of carbon atoms of from C4-C24, or a mixture thereof.
11. A use or a delivery system according to Claim 10, in which the, or each, unsaturated fatty acid has a hydrocarbon chain with C14-C24 and is preferably selected from palmitoleic, oleic, linoleic, alpha and gamma linolenic, arachidonic, eicosapentanoic and tetracosenoic acids and their monoglycerides, or a mixture thereof.
12. A use or a delivery system according to Claim 10, in which the, or each, saturated fatty acid has a hydrocarbon chain with C4-C18 and is preferably selected from butyric, isobutyric, succinic, caproic, adipic, caprylic, capric, lauric, myristic, palmitic and stearic acids and their monoglycerides, or a mixture thereof.
13. A use or a delivery system according to any one of the preceding claims, further incorporating at least one organic acid or a salt or ester thereof, or a mixture thereof.
14. A use or a delivery system according to Claim 13, in which the organic acid is selected from glycolic, oxalic, lactic, glyceric, tartronic, malic, maleic, fumaric, tartaric, malonic, glutaric, propenoic, cis or trans butenoic and citric acids or their salts or esters, or a mixture thereof.
15. A use or a delivery system according to any one of the preceding claims, further incorporating an anti-oxidant, preferably alpha-tocopherol.
16. A use or a delivery system according to any one of Claims 2 to 15 in the form of a solution for parenteral infusion for systemic treatment or prevention of infection.
17. A use or a delivery system according to any one of Claims 2 to 15 in the form of an ointment for topical application in the prevention or treatment of skin infection.
18. A use or a delivery system according to any one of Claims 2 to 15 in the form of an intravaginal cream or gel or a pessary for preventing or treating recurring Candida albicans infection.
19. A use or a delivery system according to any one of Claims 2 to 15 in the form of a surgical dressing for use in the prevention or treatment of infection.
20. A use or a delivery system according to any one of Claims 2 to 15 in the form of a medicament for mucosal application to the eye, nose, mouth, intestine or genitalia.
21. A use or a delivery system according to Claim 20 in the form of an eye drop for the prevention or treatment of infections of the eye.
22. A use or a delivery system according to Claim 20 in the form of a nasal spray for inhibiting transfer of antibiotic resistant organisms from a carrier.
23. A use or a delivery system according to Claim 20 in the form of a food or drink for use as a prophylactic agent against intestinal infection.
24. A use or a delivery system according to Claim 20 in the form of an oral healthcare formulation selected from a toothpaste, chewing gum, mouthwash or other dentifrice to improve dental hygiene or as a prophylactic agent against oral disease.
25. A use or a delivery system according to any one of Claims 7 to 24, when dependent on any one of Claims 1 to 5, in which the hydrolysed milk serum or milk whey is present in a concentration range of 0.5 to 25 mg/ml.
26. A use or a delivery system according to any one of the preceding claims, in which the milk apoprotein, or the mixture thereof, is present in a concentration range of 0.5-10 mg/ml, preferably 3-7 mg/ml.
27. A use or a delivery system according to any one of Claims 9 to 12, in which the free fatty acid, or the monoglyceride thereof; or the mixture thereof, is present in a concentration range of 0.5-5 mg/ml.
28. A use or a delivery system according to Claim 13 or 14, in which the organic acid or the salt or ester thereof, or the mixture thereof, is present in a concentration range of 0.5-5 mg/ml.
29. A use or a delivery system according to any one of Claims 9 to 12, and 27, in which the milk apoprotein or the mixture thereof; and the free fatty acid or the monoglyceride thereof, or the mixture thereof are administered either simultaneously or sequentially, within 6 hours in either order.
30. A use or a delivery system according to any one of Claims 13, 14 and 28, when dependent on any one of Claims 1 to 8, in which the milk apoprotein or the mixture thereof; and the organic acid or the salt or ester thereof or the mixture thereof, are administered either simultaneously or sequentially within 6 hours in either order.
31. A use or a delivery system according to any one of Claims 13, 14 and 28, when dependent on any one of Claims 9 to 12, in which the milk apoprotein or the mixture thereof; the free fatty acid or the monoglyceride or the mixture thereof; and the organic acid or the salt or ester thereof or the mixture thereof, are administered either simultaneously or sequentially within 6 hours of each other, in any order.
32. A use or a delivery system according to any one of Claims 2 to 1 S for cosmetic skincare.
CA2458146A 2001-08-23 2002-08-20 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection Expired - Fee Related CA2458146C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IES2001/0780 2001-08-23
IES20010780 2001-08-23
PCT/IE2002/000121 WO2003018049A2 (en) 2001-08-23 2002-08-20 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection

Publications (2)

Publication Number Publication Date
CA2458146A1 true CA2458146A1 (en) 2003-03-06
CA2458146C CA2458146C (en) 2012-07-24

Family

ID=11042830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2458146A Expired - Fee Related CA2458146C (en) 2001-08-23 2002-08-20 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection

Country Status (15)

Country Link
US (2) US7687074B2 (en)
EP (1) EP1427436B1 (en)
JP (1) JP4532900B2 (en)
KR (1) KR100907959B1 (en)
CN (1) CN1578670B (en)
AT (1) ATE399562T1 (en)
AU (1) AU2002356112B2 (en)
CA (1) CA2458146C (en)
DE (1) DE60227389D1 (en)
DK (1) DK1427436T3 (en)
ES (1) ES2309228T3 (en)
NZ (1) NZ531639A (en)
PT (1) PT1427436E (en)
RU (1) RU2305547C2 (en)
WO (1) WO2003018049A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863168A1 (en) * 2003-12-04 2005-06-10 Centre Nat Rech Scient Antibacterial agents comprising gamma--butyrolactone degradation pathway inducers, e.g. succinate semialdehyde, useful in human or veterinary medicine, plant or foodstuff protection or disinfection
KR20070040381A (en) * 2004-07-01 2007-04-16 셰펜스 아이 리써치 Compositions and methods for treating eye disorders and conditions
BRPI0616323A2 (en) * 2005-09-20 2011-06-14 Prolacta Bioscience Inc Method for determining whether a donated mammary fluid was obtained from a specific individual
WO2007061942A2 (en) 2005-11-18 2007-05-31 Glanbia Nutritionals (Ireland) Ltd. Compositions for disrupting and inhibiting reconstitution of wound biofilm
JP5017531B2 (en) * 2006-09-11 2012-09-05 株式会社アップウェル Mouth cleaner
US20100317734A1 (en) * 2007-12-04 2010-12-16 Michael Anthony Folan Free fatty acid blends and use thereof
JP2009190994A (en) * 2008-02-13 2009-08-27 Kitasato Institute Anti-influenza virus agent and method for producing its active ingredient
US20090311236A1 (en) * 2008-06-11 2009-12-17 Immune @Work, Inc. Therapeutic Peptide Compositions And Methods Of Making And Using Same
EP2316445A4 (en) * 2008-06-11 2011-12-21 Ricom Corp HUMAN beta3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME
US8808345B2 (en) * 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
WO2010082587A1 (en) * 2009-01-13 2010-07-22 株式会社大気倶楽部 Adsorbent for suspension in air
KR101119538B1 (en) * 2009-06-10 2012-02-22 장선호 A composition comprising sialic acid-containing whey protein for the prevention and treatment of influenza virus infectious disease
WO2011061237A1 (en) 2009-11-17 2011-05-26 Michael Anthony Folan Antimicrobial compositions containing free fatty acids
UY33548A (en) * 2010-08-06 2012-02-29 Eurand Pharmaceuticals Inc PREDIGERATED NUTRITIONAL FORMULA
KR101355018B1 (en) * 2010-12-13 2014-01-24 노부오 구보 A composition comprising sialic acid-containing whey protein for preventing animal feeding addition and inclused animal feeding of influenza virus infectious disease
RU2494726C2 (en) * 2011-04-11 2013-10-10 Общество с Ограниченной Ответственностью "Производственная Торговая Компания "Лактив" Method for preventing and treating fungal infection in patients with voice prostheses
EP3150257A1 (en) * 2015-09-30 2017-04-05 Buga, Doris A method for producing a composition for strengthening the immune system
CA3026402A1 (en) 2017-12-05 2019-06-05 James F. Kane Water-soluble cannabinoids and methods of making same
US11298379B2 (en) * 2020-04-16 2022-04-12 James F. Kane Compositions comprising milk fat globules and methods of making same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2796378A (en) * 1954-04-09 1957-06-18 Jr Edgar A Ferguson Methionine free reaction product of a water-soluble copper salt and lactalbumin hydrolysate as fungicide
GB1050756A (en) * 1964-09-10 1900-01-01
US4397927A (en) * 1982-03-25 1983-08-09 Brog Roy A Imitation milk compositions and aqueous dispersions prepared therefrom
WO1986004217A2 (en) * 1985-01-18 1986-07-31 Kailash Kumar Gauri Protein hydrolysates, production process and drugs containing th em
JPS62249931A (en) 1986-04-21 1987-10-30 Morinaga Milk Ind Co Ltd Antibacterial composition
JPH085798B2 (en) * 1987-02-02 1996-01-24 紀夫 多田 Antibacterial agent
ES2043279T3 (en) * 1989-06-07 1993-12-16 Kao Corp EDIBLE EMULSION OF OIL IN WATER.
JP2673320B2 (en) 1990-01-25 1997-11-05 雪印乳業株式会社 Anti-cariogenic agent attachment inhibitor
JPH04159232A (en) 1990-08-21 1992-06-02 Yakult Honsha Co Ltd Oral agent composition for prevention and therapy of opportunistic infectious disease
CA2094570A1 (en) * 1992-05-27 1993-11-28 Jerome F. Trumbetas Enzymatic protein process and product
EP0665721A1 (en) 1992-10-30 1995-08-09 Cancer Research Fund Of Contra Costa Anti-diarrheic product and method of treating rotavirus-associated infection
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
EP0776214B1 (en) * 1994-08-16 1999-07-28 Hemant Sabharwal Antibacterial composition containing multimeric alpha-lactalbumin
JP4233615B2 (en) 1996-08-22 2009-03-04 森永乳業株式会社 Oral anti-human onychomycosis and / or pharmaceuticals for human foot ringworm other than onychomycosis
ES2217532T3 (en) * 1997-01-09 2004-11-01 Morinaga Milk Industry Co., Ltd. TABLETS OF LACTOFERRINA.
IE970541A1 (en) 1997-07-25 1999-01-27 Michael Anthony Folan Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity
JP4129566B2 (en) * 1997-09-05 2008-08-06 大塚製薬株式会社 Liver fat accumulation inhibiting composition and food additive for liver fat accumulation inhibiting
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AUPP051497A0 (en) 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
NZ509101A (en) 1998-06-26 2003-07-25 N Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
GB9903584D0 (en) * 1999-02-18 1999-04-07 Univ Leeds Modified calycins
JP3662445B2 (en) * 1999-06-30 2005-06-22 花王株式会社 Water-in-oil emulsified fat composition
DE60210602T2 (en) * 2001-05-23 2007-05-16 Nutricopia, Inc. FROZEN NUTRITIONAL MEALS AND METHOD FOR THE PRODUCTION THEREOF
US20030165606A1 (en) 2001-07-18 2003-09-04 Lasekan John B. Anti-regurgitation formula and uses thereof
EP1319407A1 (en) * 2001-12-14 2003-06-18 Montoie Import-Export S.A. Pharmaceutical composition for topical treatment of skin disorders and skin wounds

Also Published As

Publication number Publication date
KR100907959B1 (en) 2009-07-16
EP1427436A2 (en) 2004-06-16
JP4532900B2 (en) 2010-08-25
RU2004108040A (en) 2005-09-27
DK1427436T3 (en) 2008-10-13
ATE399562T1 (en) 2008-07-15
US20050042299A1 (en) 2005-02-24
DE60227389D1 (en) 2008-08-14
US7687074B2 (en) 2010-03-30
US20100209526A1 (en) 2010-08-19
JP2005501863A (en) 2005-01-20
EP1427436B1 (en) 2008-07-02
PT1427436E (en) 2008-09-08
ES2309228T3 (en) 2008-12-16
RU2305547C2 (en) 2007-09-10
NZ531639A (en) 2006-02-24
WO2003018049A2 (en) 2003-03-06
AU2002356112B2 (en) 2007-11-08
WO2003018049A3 (en) 2003-11-06
US7972629B2 (en) 2011-07-05
CN1578670A (en) 2005-02-09
CA2458146C (en) 2012-07-24
KR20040041579A (en) 2004-05-17
CN1578670B (en) 2013-09-04

Similar Documents

Publication Publication Date Title
CA2458146A1 (en) Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
Al-Jabri Honey, milk and antibiotics
CA2688736C (en) Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
JP2005501863A5 (en)
JP2011505415A5 (en)
JP4847756B2 (en) Human β-defensin secretion promoter
EP1040833A1 (en) Bone resorption suppressing agent
US20200171077A1 (en) Compositions and methods for treating and preventing bacterial infections
JP2013075927A (en) Biofilm formation inhibitor
KR20080106183A (en) Methods and composition for bactericide, bacteriostatic and anti-inflammation
EP1089755B1 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
US7311925B2 (en) Methods and compositions for blocking microbial adherence to eukaryotic cells
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
US6936635B1 (en) Composition for the treatment of respiratory disorders and a method for its use
ES2964356T3 (en) Composition based on a mixture of biological factors isolated from colostrum and ozonated vegetable oils for use in the treatment of vaginitis and vaginosis
JPH0559092B2 (en)
JPH05178759A (en) Immunopotentiator, therapeutic agent for infectious disease and immunopotentiating food
JP2004529095A (en) Prevention of ventilator-associated pneumonia by oral administration of antibacterial IB-367 peptide
EP0974360A2 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
WO2023153945A1 (en) Combination, therapeutic uses and prophylactic uses
US20140187475A1 (en) Lantibiotic Compositions and Methods For Preventing or Treating Mastitis
AU2002248434A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831